Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity, Inc. stock logo
CELU
Celularity
$3.03
+37.7%
$2.06
$1.00
$5.22
$72.57M0.74377,055 shs746,361 shs
LianBio stock logo
LIAN
LianBio
$0.06
+10.0%
$0.35
$0.27
$4.99
$5.94M0.231.04 million shs39,001 shs
Mural Oncology PLC stock logo
MURA
Mural Oncology
$2.50
+0.4%
$2.57
$0.95
$4.74
$43.17M3.031.29 million shs99,378 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$2.45
+0.8%
$2.22
$0.97
$9.79
$11.76M0.912.46 million shs117,016 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity, Inc. stock logo
CELU
Celularity
0.00%+43.60%+69.27%+94.86%-5.02%
LianBio stock logo
LIAN
LianBio
0.00%-87.11%-85.53%-72.50%-81.67%
Mural Oncology PLC stock logo
MURA
Mural Oncology
0.00%+2.46%+1.21%-7.41%-28.16%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.00%+6.06%+3.81%-10.26%-48.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celularity, Inc. stock logo
CELU
Celularity
0.0276 of 5 stars
0.00.00.00.00.61.70.0
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.8139 of 5 stars
3.35.00.00.00.01.71.3
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
1.978 of 5 stars
3.52.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celularity, Inc. stock logo
CELU
Celularity
0.00
N/AN/AN/A
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.50
Moderate Buy$12.00380.00% Upside
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.00
Buy$14.00471.43% Upside

Current Analyst Ratings Breakdown

Latest PHIO, MURA, CELU, and LIAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/5/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celularity, Inc. stock logo
CELU
Celularity
$54.22M1.34N/AN/A$0.37 per share8.19
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/A$8.22 per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$0.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celularity, Inc. stock logo
CELU
Celularity
-$57.89M-$2.65N/AN/A-106.77%-271.88%-42.82%7/21/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$7.15M-$6.42N/A0.65N/AN/A-105.65%-89.19%8/13/2025 (Estimated)

Latest PHIO, MURA, CELU, and LIAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.36N/AN/AN/AN/AN/A
8/12/2025N/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$1.13N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$2.12-$1.93+$0.19-$1.93N/AN/A
5/8/2025Q4 2024
Celularity, Inc. stock logo
CELU
Celularity
-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celularity, Inc. stock logo
CELU
Celularity
4.07
0.38
0.28
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/A
5.08
5.08
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
10.58
10.58

Institutional Ownership

CompanyInstitutional Ownership
Celularity, Inc. stock logo
CELU
Celularity
19.02%
LianBio stock logo
LIAN
LianBio
74.85%
Mural Oncology PLC stock logo
MURA
Mural Oncology
80.21%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%

Insider Ownership

CompanyInsider Ownership
Celularity, Inc. stock logo
CELU
Celularity
22.10%
LianBio stock logo
LIAN
LianBio
7.59%
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.20%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celularity, Inc. stock logo
CELU
Celularity
22023.95 million18.66 millionOptionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Mural Oncology PLC stock logo
MURA
Mural Oncology
11917.27 million16.89 millionOptionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
104.80 million4.77 millionNot Optionable

Recent News About These Companies

Best Value Stocks to Buy for May 28th
New Strong Buy Stocks for May 28th
Best Momentum Stocks to Buy for April 23rd
Best Value Stocks to Buy for April 23rd
Phio Pharmaceuticals Corp. Common Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celularity stock logo

Celularity NASDAQ:CELU

$3.03 +0.83 (+37.73%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.85 -0.18 (-5.94%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.06 +0.01 (+10.00%)
As of 07/18/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Mural Oncology stock logo

Mural Oncology NASDAQ:MURA

$2.50 +0.01 (+0.40%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.50 0.00 (-0.20%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$2.45 +0.02 (+0.82%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.48 +0.03 (+1.22%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.